Higher heart risk seen with Abbott dissolving stent after two years: study

Higher heart risk seen with Abbott dissolving stent after two years: studyBy Bill Berkrot WASHINGTON (Reuters) – Patients who received Abbott Laboratories’ novel dissolving vascular stent had a significantly higher rate of serious adverse heart events than those treated with the company’s widely used Xience drug-coated metal stent two years after implantation, according to data presented on Saturday. New guidelines for blood vessel size and proper implantation techniques put in place for the new Absorb stent since the study began, however, should lead to better results, researchers said. “The difference between Absorb and Xience when they’re both implanted in properly-sized vessels with good procedural technique is likely to be quite modest and possibly not clinically important,” said Dr. Stephen Ellis, director of interventional cardiology at Cleveland Clinic, who presented the data at the American College of Cardiology scientific meeting in Washington.



Yahoo News – Latest News & Headlines